Talazoparib Improves Overall Survival in Metastatic CRPC

[ad_1]

(MedPage Today) — An analysis of a phase III trial presented at this year’s American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium showed that adding the PARP inhibitor talazoparib (Talzenna) to enzalutamide (Xtandi) significantly…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/gucsvideopearls/114637

Author :

Publish date : 2025-03-13 18:08:00

Copyright for syndicated content belongs to the linked Source.